These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25354112)

  • 21. Common stem--lutamide.
    Prescrire Int; 2014 Oct; 23(153):236. PubMed ID: 25964967
    [No Abstract]   [Full Text] [Related]  

  • 22. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR; Hussain MH
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen receptor antagonists for prostate cancer therapy.
    Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
    Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Mechanism and side effect of endocrine therapy].
    Tsuda M; Ishiguro H; Saji S
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():291-7. PubMed ID: 25831770
    [No Abstract]   [Full Text] [Related]  

  • 25. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration.
    Lin GW; Yao XD; Ye DW
    BJU Int; 2011 Apr; 107(8):1326-7; author reply 1327. PubMed ID: 21929520
    [No Abstract]   [Full Text] [Related]  

  • 26. Management of hormone-sensitive metastatic prostate cancer. Update on hormonal therapy.
    Figg WD; Feuer JA; Bauer KS
    Cancer Pract; 1997; 5(4):258-63. PubMed ID: 9250085
    [No Abstract]   [Full Text] [Related]  

  • 27. Novel drugs targeting the androgen receptor pathway in prostate cancer.
    Mateo J; Smith A; Ong M; de Bono JS
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):567-79. PubMed ID: 24390422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.
    Mitsiades N
    Cancer Res; 2013 Aug; 73(15):4599-605. PubMed ID: 23887973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of the androgen receptor inhibitor enzalutamide on the pharmacokinetics of dolutegravir and tenofovir: a case report.
    Londero A; Fusi M; Cinausero M; Tascini C; Gervasoni C; Cattaneo D
    AIDS; 2022 Sep; 36(11):1603-1605. PubMed ID: 35979833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phototoxic eruption caused by enzalutamide (Xtandi).
    Navarro-Triviño FJ; Ruiz-Villaverde R
    Contact Dermatitis; 2021 Jan; 84(1):64-65. PubMed ID: 32865823
    [No Abstract]   [Full Text] [Related]  

  • 31. Pigs in a blanket: an unusual presentation of malignant ascites in prostatic adenocarcinoma.
    Samankan S; Taherian M; Aghighi M; Crossland D
    BMJ Case Rep; 2019 Nov; 12(11):. PubMed ID: 31732542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful use of the potent enzyme inducer enzalutamide in a treatment-experienced HIV-positive male with prostate cancer.
    Nhean S; Bravo J; Sheehan NL; Walmsley S; Tilley D; Tseng AL
    AIDS; 2018 Nov; 32(17):2640-2642. PubMed ID: 30379691
    [No Abstract]   [Full Text] [Related]  

  • 33. Enzalutamide Bests Older NSAAs in mHSPC.
    Cancer Discov; 2019 Aug; 9(8):OF7. PubMed ID: 31164340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The unaffordable cost of M&A-driven drug prices.
    Goozner M
    Mod Healthc; 2016 Oct; 46(35):24. PubMed ID: 30452799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enzalutamide and sleep apnea: an emerging central nervous system side-effect?
    Labrize F; Cany L; Massard C; Loriot Y; Sargos P; Gross-Goupil M; Roubaud G
    Ann Oncol; 2016 Jan; 27(1):206. PubMed ID: 26445811
    [No Abstract]   [Full Text] [Related]  

  • 36. [Prostate cancer chemotherapy, myth or reality?].
    Rioja Sanz LA
    Actas Urol Esp; 2005 Sep; 29(8):723-4. PubMed ID: 16304901
    [No Abstract]   [Full Text] [Related]  

  • 37. Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?
    Higano C
    Nat Rev Urol; 2019 Jun; 16(6):335-336. PubMed ID: 31040439
    [No Abstract]   [Full Text] [Related]  

  • 38. Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer.
    Butcher G; Howard H; Sathianathen N; Catto JWF; Murphy DG
    Eur Urol; 2019 Dec; 76(6):872-873. PubMed ID: 31352977
    [No Abstract]   [Full Text] [Related]  

  • 39. Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer.
    Alcaraz A
    Eur Urol; 2020 Feb; 77(2):286-287. PubMed ID: 31522916
    [No Abstract]   [Full Text] [Related]  

  • 40. Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer.
    Huebner NA; Shariat SF
    Eur Urol; 2020 Jan; 77(1):132-133. PubMed ID: 31542306
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.